Clinical Trial Update: A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms. [Phase 2]

View source ↗

Summary

A Phase 2 study of PF-06823859 in adults with active lupus erythematosus with skin involvement has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• PF-06823859

Snippet

Sponsor: Pfizer | Conditions: Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous | Phase 2 | Status: TERMINATED